[go: up one dir, main page]

Grisch-Chan et al., 2019 - Google Patents

State-of-the-art 2019 on gene therapy for phenylketonuria

Grisch-Chan et al., 2019

View HTML @Full View
Document ID
901852537993230939
Author
Grisch-Chan H
Schwank G
Harding C
Thöny B
Publication year
Publication venue
Human gene therapy

External Links

Snippet

Phenylketonuria (PKU) is considered to be a paradigm for a monogenic metabolic disorder but was never thought to be a primary application for human gene therapy due to established alternative treatment. However, somewhat unanticipated improvement in …
Continue reading at journals.sagepub.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses
    • C12N2750/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses ssDNA Viruses
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses

Similar Documents

Publication Publication Date Title
Grisch-Chan et al. State-of-the-art 2019 on gene therapy for phenylketonuria
Harding et al. Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria
Song et al. In vivo genome editing partially restores alpha1-antitrypsin in a murine model of AAT deficiency
Zhang et al. Adenine base editing in vivo with a single adeno-associated virus vector
Wang et al. Hepatic gene transfer in neonatal mice by adeno-associated virus serotype 8 vector
Chandler et al. Recombinant adeno-associated viral integration and genotoxicity: insights from animal models
Yang et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Chandler et al. Gene therapy for methylmalonic acidemia: past, present, and future
Salido et al. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer
Armbruster et al. Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy
Paneda et al. Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria
Karumuthil-Melethil et al. Novel vector design and hexosaminidase variant enabling self-complementary adeno-associated virus for the treatment of Tay-Sachs disease
Dirren et al. Intracerebroventricular injection of adeno-associated virus 6 and 9 vectors for cell type–specific transgene expression in the spinal cord
Wang et al. AAV8-mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta)
Ding et al. Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer
Ding et al. Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system
Francis et al. Preclinical biodistribution, tropism, and efficacy of oligotropic AAV/Olig001 in a mouse model of congenital white matter disease
Martinez et al. State‐of‐the‐art 2023 on gene therapy for phenylketonuria
Westhaus et al. AAV-p40 bioengineering platform for variant selection based on transgene expression
Ling et al. Development of optimized AAV serotype vectors for high-efficiency transduction at further reduced doses
Yagi et al. Complete restoration of phenylalanine oxidation in phenylketonuria mouse by a self‐complementary adeno‐associated virus vector
Hu et al. Myocyte-mediated arginase expression controls hyperargininemia but not hyperammonemia in arginase-deficient mice
Nathwani et al. Liver gene therapy
An et al. In vivo base editing extends lifespan of a humanized mouse model of prion disease
Duff et al. Gene therapy for urea cycle defects: An update from historical perspectives to future prospects